Race Oncology Limited's (ASX:RAC) Daniel Tillett speaks to Proactive's Andrew Scott following the release of positive preclinical results for its Bisantrene drug in breast cancer. It was part of a collaborative research program between Race and The University of Newcastle with the aim of identifying combinations of current breast cancer drugs that when paired with Bisantrene show equivalent efficacy to existing treatment options, but with significantly reduced serious side effects.
Race Oncology's Daniel Tillett details positive preclinical results for Bisantrene in breast cancer
Quick facts: Race Oncology Ltd
Price: 1.745 AUD
Market Cap: $225.91 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Race Oncology Ltd named herein, including the promotion by the Company of Race Oncology Ltd in any Content on the Site, the Company receives...FOR OUR FULL DISCLAIMER CLICK HERE